L-Carnitine API Manufacturers

Looking for L-Carnitine API 541-15-1?

Description:

Here you will find a list of producers, manufacturers and traders of L-Carnitine. You can sort by certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.

API | Excipient name:

L-Carnitine 

Synonyms:

Carnicor , Carnitene , Carnitine , Carnitor , Karnitin , L-Carnitine , Levocarnitin , Levocarnitina , Levocarnitinum , Vitamin bt  

Cas Number:

541-15-1 

DrugBank number:

DB00583 

Unique Ingredient Identifier:

0G389FZZ9M

L-Carnitine is a type of Means in metabolic disorders

The pharmaceutical API subcategory of means in metabolic disorders refers to a group of active pharmaceutical ingredients (APIs) that are utilized in the treatment of various metabolic disorders. Metabolic disorders are medical conditions that involve disruptions in the normal metabolic processes of the body, such as those related to glucose metabolism, lipid metabolism, or hormone regulation.

The means in metabolic disorders APIs encompass a diverse range of compounds that target specific pathways or enzymes involved in metabolic regulation. These APIs play a crucial role in managing conditions like diabetes, obesity, hyperlipidemia, and hormonal imbalances. They are often incorporated into medications designed to improve metabolic function and restore the balance of key biomolecules in the body.

Common APIs in this subcategory include biguanides, sulfonylureas, thiazolidinediones, dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, and sodium-glucose co-transporter 2 (SGLT2) inhibitors. These APIs exert their effects through various mechanisms such as enhancing insulin sensitivity, increasing insulin secretion, reducing glucose production, and promoting weight loss.

The development of means in metabolic disorders APIs involves extensive research and rigorous testing to ensure their efficacy, safety, and compatibility with existing treatment regimens. Pharmaceutical companies collaborate with researchers and regulatory authorities to conduct clinical trials and obtain necessary approvals before these APIs can be integrated into commercial medications.

In summary, means in metabolic disorders APIs are a vital component of pharmaceutical interventions aimed at managing metabolic disorders. By targeting specific metabolic pathways, these APIs contribute to improving patient outcomes and enhancing their overall quality of life.

L-Carnitine (Means in metabolic disorders), classified under Metabolic Bone Disease Agents

Metabolic Bone Disease Agents are a category of pharmaceutical active pharmaceutical ingredients (APIs) that are specifically designed to treat and manage conditions related to the bones and their metabolism. These agents play a crucial role in the treatment of various metabolic bone diseases, including osteoporosis, Paget's disease, and rickets.

The primary function of Metabolic Bone Disease Agents is to regulate bone remodeling and maintain bone health. They achieve this by targeting specific pathways involved in bone metabolism, such as osteoclast and osteoblast activity, calcium regulation, and vitamin D metabolism.

These APIs are commonly used in the development of medications, including oral tablets, injectables, and topical formulations, for the effective treatment of metabolic bone diseases. They are carefully formulated to optimize their pharmacokinetic and pharmacodynamic properties, ensuring maximum efficacy and minimal side effects.

Metabolic Bone Disease Agents encompass a range of substances, including bisphosphonates, selective estrogen receptor modulators (SERMs), calcitonin, and vitamin D analogs. These APIs act through different mechanisms to address specific aspects of bone health, such as inhibiting bone resorption, promoting bone formation, or regulating calcium levels.

In conclusion, Metabolic Bone Disease Agents are a vital category of pharmaceutical APIs used in the development of medications for the treatment and management of various metabolic bone diseases. These agents target specific pathways involved in bone metabolism to regulate bone remodeling, enhance bone health, and alleviate the symptoms associated with these conditions.

• Sinoway industrial Co.,Ltd from China, product country of origin China
• Xi'an Tian Guangyuan Biotech Co.,Ltd from China, product country of origin China
• Rochem International, Inc. from United States, product country of origin United States
• Xi'an ZB Biotech Co., Ltd from China, product country of origin China
• Otto Brandes GmbH from Germany, product country of origin China
• ChengDa Pharma from China, product country of origin China
• Zhejiang Tiantai from China, product country of origin China
• Kaiyuan Hengtai Pharma Co Ltd from China, product country of origin China

Let the supplier know whether you are looking for a product with a specific monograph such as EP (Ph. Eur.), USP, JP, BP or another quality. Or, whether you are looking for hydrochloride (HCl), anhydricum, base, micronisatum or a specific purity.

You can use the filters to find high-quality suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our FAQ page or use the chat box in the corner to get more information about Pharmaoffer.